Current treatment status of HR+/HER 2-advanced breast cancer
10.3969/j.issn.1005-6483.2024.07.030
- VernacularTitle:激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的治疗现状
- Author:
Yu WANG
1
;
Bin SHAO
;
Yang LIU
;
Song WANG
;
Jianguo ZHANG
Author Information
1. 150086 黑龙江省牡丹江市肿瘤医院头颈乳腺三科;哈尔滨医科大学附属第二医院乳腺外科
- Keywords:
hormone receptor positive;
advanced breast cancer;
CDK4/6 inhibitor
- From:
Journal of Clinical Surgery
2024;32(7):780-782
- CountryChina
- Language:Chinese
-
Abstract:
At present,the incidence of breast cancer has been the first in the world,and hormone receptor-positive(HR+)/human epidermal growth factor receptor 2-negative(HER2-)advanced breast cancer has seriously affected the prognosis of patients.In the past,the therapeutic drugs were mainly third-generation aromatase inhibitors(AI)and fulvestrant.In recent years,the era of endocrine therapy combined with cyclin-dependent kinase4/6(CDK4/6)inhibitors has begun.Different CDK4/6 inhibitors have different related adverse events,and they need to evaluate the physical condition of patients and develop a treatment plan,but neutropenia is prevalent.Everolimus,Alpelisib,and Chidamide are second-line therapeutic drugs.
